Abiomed Impella RP: FDA Class I Correction for Inaccurate Flow Readings
Abiomed has issued an Urgent Medical Device Correction for its Impella RP with SmartAssist and Impella RP Flex with SmartAssist systems due to potential inaccuracies in displayed pump performance data.
The U.S. FDA has classified this action as a Class I recall, indicating that continued reliance on affected device outputs without following updated instructions may result in serious injury or death.
What Is the Issue?
The correction involves a potential malfunction of the differential pressure (dP) sensor, which is used to calculate and display key hemodynamic parameters. If sensor drift occurs over time, the system may display inaccurate values, including the pump flow rate, pulmonary artery (PA) placement signal, pulmonary artery pulsatility index (PAPi), and central venous (CV) placement signal.
These inaccuracies may lead clinicians to make inappropriate clinical decisions, including incorrect pump setting (P-level) adjustments or unnecessary pump exchanges.
Importantly, the issue does not affect the pump’s ability to provide hemodynamic support, but rather the accuracy of displayed data used for clinical decision-making.
Affected Devices
Devices affected by the correction are the Impella RP with SmartAssist and the Impella RP Flex with SmartAssist. The devices are temporary heart pumps used in hospital settings to provide right ventricular support in patients with acute right heart failure.
Reported Adverse Events
As of January 15, there were 22 serious injuries and no deaths reported.
Required Actions for Clinicians
Abiomed and the FDA recommend that clinicians should not rely solely on Automated Impella Controller (AIC) displayed values. Instead, patient management should be guided by independent clinical assessment. Monitor patient hemodynamics with approved diagnostic devices and verify the device positioning by using imaging prior to clinical intervention.
Pump performance should be evaluated using P-level flow rates provided in the Instructions for Use (IFU) rather than displayed values on the AIC. Clinicians should also trend pump metrics over time, recognizing that abrupt changes or discrepancies may indicate issues with positioning, patient condition, or pump performance.
Healthcare facilities are advised to distribute this information to all relevant personnel and ensure awareness across teams responsible for device use, storage, and transport.
Contact Information
For questions or adverse events, contact Abiomed, Inc. by email at onemed-field-actions@its.jnj.com.
MDP Analysis
This correction highlights several critical regulatory and quality system considerations.
Software / Data Integrity (IEC 62304)
Although the device hardware continues to function, the issue lies in data accuracy and interpretation, a core concern in software-driven medical devices. This is a classic example of correct therapy, incorrect data, and a high-risk scenario for clinical decision-making.
Risk Management (ISO 14971)
The failure mode reflects insufficient control of sensor drift over time and the risks associated with overreliance on displayed parameters. This aligns with hazards related to incorrect clinical decisions and misinterpretation of device output.
Human Factors and Clinical Workflow
Clinicians may naturally rely on device-displayed values, and this event underscores the need for redundant verification (imaging, diagnostics), clear labeling of device limitations, and clinician training on data interpretation vs direct measurement.
Post-Market Surveillance
The identification of 22 serious injuries demonstrates the importance of real-world performance monitoring and the role of trend analysis in detecting latent system issues.
System-Level Insight
This is not a mechanical failure; it is a measurement and feedback loop failure. In modern devices, data is relied on for decision making, so data integrity is closely tied to patient safety.
Bottom Line
This correction reinforces a critical principle in advanced medical devices, that safe device performance depends not only on mechanical function, but also on the accuracy and reliability of the data used to guide clinical decisions. Manufacturers must ensure that sensor performance remains stable over time, data limitations are clearly communicated, and risk controls account for clinical reliance on displayed values.
Links
Read the FDA’s announcement here.
Pharmacal Recalls MG217 Eczema Cream
Pharmacal Recalls MG217 Eczema Cream Due to Staphylococcus aureus ContaminationFDA posts nationwide recall after microbial contamination found in topical skin treatment Pharmacal has voluntarily recalled one lot of MG217 Multi-Symptom Treatment Cream & Skin...
Cefazolin Injection Recalled Due to Cardboard in Sterile IV Solution
Baxter Recalls Cefazolin Injection Sterile IV SolutionCardboard Particulate Matter Found in a Sterile Intravenous Infusion Bag Baxter International has voluntarily recalled one lot of Cefazolin in Dextrose Injection, USP, 2 g/100 mL after a report of cardboard...
FDA Closes Moringa Salmonella Outbreak Investigation
The U.S. Food and Drug Administration and the Centers for Disease Control and Prevention have concluded their investigation into a multistate Salmonella Typhimurium outbreak linked to MOGO-brand moringa powder capsules distributed by MOGO Moringa LLC of St. Louis,...
Why the Sudden Focus on Testosterone?
New Military Screening Program Raises Questions About Science, Strategy and TransparencyThe Trump administration's decision to begin annual testosterone screening for active-duty and reserve service members age 30 and older has generated headlines and a growing number...
Arrow Corrects Kits With Recalled Injectable Medications
FDA Classifies Field Correction As Class I Recall Due to Risk of Serious Injury The U.S. Food and Drug Administration (FDA) has classified a correction issued by Arrow International, a subsidiary of Teleflex, as a Class I recall after certain convenience kits were...
FDA Approves First Oral PCSK9 Inhibitor for High Cholesterol
FDA Approves Lipfendra, the First Oral PCSK9 Inhibitor for High CholesterolLipfendra offers patients a once-daily pill alternative to injectable PCSK9 therapies The U.S. Food and Drug Administration (FDA) has approved Lipfendra (enlicitide), the first oral medication...
